Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152582 | 0.95 | BRD4 (0.39) | BRD4HRH3ADORA2A | |
| SCHEMBL5149284 | 0.89 | ADORA3 (0.43) | BRD4HIF1AADORA2APKMTP53 | |
| SCHEMBL5149121 | 0.88 | ADORA2A (0.40) | GSK3BBRD4BACE1ADORA2A | |
| SCHEMBL5149018 | 0.88 | TLR8 (0.46) | CYP1A2CYP3A4CYP2C19TP53SMN1; SMN2 | |
| SCHEMBL5149223 | 0.87 | HIF1A (0.47) | HIF1AAPPCYP1A2ADORA2A | |
| SCHEMBL5149119 | 0.87 | GSK3B (0.39) | GSK3BHIF1AAPPPDE5AADORA2A | |
| SCHEMBL5151060 | 0.87 | ADORA2A (0.39) | CYP3A4ADORA2ATP53 | |
| SCHEMBL5149196 | 0.84 | KAT2B (0.47) | HRH3CYP3A4CYP2D6 | |
| SCHEMBL5152508 | 0.82 | TLR9 (0.48) | HIF1ACYP1A2CYP3A4CYP2D6ADORA2A | |
| SCHEMBL5149173 | 0.82 | HTR7 (0.37) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | GSK3B 688/4885BRD4 2661/4885HIF1A 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.